Connection

FAYE M JOHNSON to Dasatinib

This is a "connection" page, showing publications FAYE M JOHNSON has written about Dasatinib.
Connection Strength

1.409
  1. Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations. Oncotarget. 2016 Jan 05; 7(1):565-79.
    View in: PubMed
    Score: 0.396
  2. A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. Oncologist. 2014 Oct; 19(10):1040-1.
    View in: PubMed
    Score: 0.361
  3. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Invest New Drugs. 2018 06; 36(3):416-423.
    View in: PubMed
    Score: 0.112
  4. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci Transl Med. 2012 May 30; 4(136):136ra70.
    View in: PubMed
    Score: 0.077
  5. Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer. Clin Cancer Res. 2011 Feb 01; 17(3):514-24.
    View in: PubMed
    Score: 0.070
  6. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010 Oct 20; 28(30):4609-15.
    View in: PubMed
    Score: 0.069
  7. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer. 2010 Mar 15; 116(6):1582-91.
    View in: PubMed
    Score: 0.066
  8. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Res. 2009 Mar 01; 69(5):1958-65.
    View in: PubMed
    Score: 0.062
  9. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res. 2007 Jul 15; 13(14):4233-44.
    View in: PubMed
    Score: 0.055
  10. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther. 2007 Jul; 6(7):1962-72.
    View in: PubMed
    Score: 0.055
  11. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6924-32.
    View in: PubMed
    Score: 0.049
  12. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways. Radiother Oncol. 2012 Nov; 105(2):241-9.
    View in: PubMed
    Score: 0.020
  13. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer. 2011 May 15; 117(10):2112-9.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.